Randomized Trialhigh evidence
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.
The Lancet. Oncology·September 25, 2026·PMID 42790445
Why it mattersAchieving MRD-negative complete response is associated with improved long-term outcomes in multiple myeloma. IberDd offers a novel, all-oral (except daratumumab) regimen with a significantly higher MRD-negative CR rate than a standard triplet, potentially improving depth of response in relapsed/refractory disease.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled